Needham Maintains Buy on Collegium Pharmaceutical, Raises Price Target to $36
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Serge Belanger maintains a 'Buy' rating on Collegium Pharmaceutical (NASDAQ:COLL) and raises the price target from $35 to $36.
August 25, 2023 | 6:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger maintains a 'Buy' rating on Collegium Pharmaceutical and raises the price target from $35 to $36. This could potentially lead to an increase in the stock's price.
The 'Buy' rating maintained by Needham indicates a positive outlook for Collegium Pharmaceutical. The increase in the price target from $35 to $36 suggests that the analyst expects the stock's price to rise in the short term. This news could potentially lead to an increase in demand for the stock, thereby driving up its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100